Kathryn J. Collier
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
16 Jun 2025 |
1,396 |
2,604
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
16 Jun 2025 |
2,325 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
16 Jun 2025 |
2,604 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.90 per share. |
16 Jun 2025 |
1,396 |
67,844
(0%)
|
0%
|
9.9 |
13,820
|
Common Stock |
Kathryn J. Collier
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. |
16 Jun 2025 |
2,325 |
62,915
(0%)
|
0%
|
8.8 |
20,460
|
Common Stock |
Kathryn J. Collier
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.90 per share. |
16 Jun 2025 |
2,604 |
65,240
(0%)
|
0%
|
9.9 |
25,780
|
Common Stock |
Preston Klassen
|
Director, President & Head of R & D |
Purchase of securities on an exchange or from another person at price $ 7.99 per share. |
03 Jun 2025 |
12,000 |
48,055
(0%)
|
0%
|
8.0 |
95,852
|
Common Stock |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Apr 2025 |
62,500 |
1,040,888
(4%)
|
0%
|
|
0
|
Common Stock |
William H. Rastetter
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Apr 2025 |
62,500 |
101,556
(0%)
|
0%
|
|
0
|
Common Stock |
David Baltimore
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Apr 2025 |
62,500 |
84,669
(0%)
|
0%
|
|
0
|
Common Stock |
David Baltimore
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Apr 2025 |
62,500 |
62,500
(0%)
|
0%
|
|
0
|
Common Stock |
Jake R. Nunn
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Apr 2025 |
62,500 |
62,500
(0%)
|
0%
|
|
0
|
Common Stock |
Pascale Witz
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Apr 2025 |
62,500 |
67,233
(0%)
|
0%
|
|
0
|
Common Stock |
Hugh Rosen
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Apr 2025 |
62,500 |
64,271
(0%)
|
0%
|
|
0
|
Common Stock |
Kathryn J. Collier
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Apr 2025 |
62,500 |
69,240
(0%)
|
0%
|
|
0
|
Common Stock |
Alice Shih-hou Huang
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Apr 2025 |
62,500 |
62,500
(0%)
|
0%
|
|
0
|
Common Stock |
Alice Shih-hou Huang
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Apr 2025 |
62,500 |
84,669
(0%)
|
0%
|
|
0
|
Common Stock |
David Baltimore
|
Director |
Purchase of securities on an exchange or from another person at price $ 1.06 per share. |
30 Jan 2025 |
19,610 |
22,169
(0%)
|
0%
|
1.1 |
20,787
|
Common Stock |
Joseph P. Hagan
|
Director, Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Jan 2025 |
1,350,000 |
1,350,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, Chief Executive Officer |
Purchase of securities on an exchange or from another person at price $ 1.09 per share. |
30 Jan 2025 |
50,000 |
260,808
(1%)
|
0%
|
1.1 |
54,260
|
Common Stock |
Preston Klassen
|
Director, President & Head of R & D |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Jan 2025 |
675,000 |
675,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Christopher Aker
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Jan 2025 |
487,500 |
487,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Jan 2025 |
562,500 |
562,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 1.26 per share. |
13 Jan 2025 |
11,764 |
210,808
(1%)
|
0%
|
1.3 |
14,860
|
Common Stock |
Joseph P. Hagan
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 1.26 per share. |
13 Jan 2025 |
115,290 |
222,572
(1%)
|
0%
|
1.3 |
145,634
|
Common Stock |
Preston Klassen
|
Director, President & Head of R & D |
Sale of securities on an exchange or to another person at price $ 1.26 per share. |
13 Jan 2025 |
31,445 |
36,055
(0%)
|
0%
|
1.3 |
39,721
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 1.26 per share. |
13 Jan 2025 |
5,088 |
49,546
(0%)
|
0%
|
1.3 |
6,427
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 1.26 per share. |
13 Jan 2025 |
38,547 |
54,634
(0%)
|
0%
|
1.3 |
48,693
|
Common Stock |
Crispina Calsada
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 1.26 per share. |
13 Jan 2025 |
38,716 |
50,566
(0%)
|
0%
|
1.3 |
48,906
|
Common Stock |
Crispina Calsada
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 1.26 per share. |
13 Jan 2025 |
5,088 |
45,478
(0%)
|
0%
|
1.3 |
6,427
|
Common Stock |
Preston Klassen
|
Director, President & Head of R & D |
Grant, award, or other acquisition of securities at price $ 1.36 per share. |
09 Jan 2025 |
37,500 |
37,500
(0%)
|
0%
|
1.4 |
51,000
|
Common Stock |
Preston Klassen
|
Director, President & Head of R & D |
Grant, award, or other acquisition of securities at price $ 1.30 per share. |
09 Jan 2025 |
30,000 |
67,500
(0%)
|
0%
|
1.3 |
39,000
|
Common Stock |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 1.30 per share. |
09 Jan 2025 |
21,000 |
89,282
(0%)
|
0%
|
1.3 |
27,300
|
Common Stock |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 1.36 per share. |
09 Jan 2025 |
62,500 |
68,282
(0%)
|
0%
|
1.4 |
85,000
|
Common Stock |
Kathryn J. Collier
|
Director |
Purchase of securities on an exchange or from another person at price $ 1.82 per share. |
25 Jul 2024 |
4,000 |
6,740
(0%)
|
0%
|
1.8 |
7,280
|
Common Stock |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 May 2024 |
60,000 |
60,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 May 2024 |
60,000 |
60,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 May 2024 |
60,000 |
60,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 May 2024 |
990,000 |
990,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Jake R. Nunn
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 May 2024 |
60,000 |
60,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Preston Klassen
|
Director, President & Head of R & D |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 May 2024 |
528,000 |
528,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Christopher Aker
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 May 2024 |
363,000 |
363,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Pascale Witz
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 May 2024 |
60,000 |
60,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Hugh Rosen
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 May 2024 |
60,000 |
60,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 May 2024 |
60,000 |
60,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 May 2024 |
462,000 |
462,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Alice Shih-hou Huang
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 May 2024 |
60,000 |
60,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 May 2024 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 May 2024 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 May 2024 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Jake R. Nunn
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 May 2024 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Pascale Witz
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 May 2024 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Hugh Rosen
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 May 2024 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 May 2024 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Alice Shih-hou Huang
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 May 2024 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 1.60 per share. |
14 Mar 2024 |
250,000 |
978,388
(4%)
|
1%
|
1.6 |
400,000
|
Common Stock |
Aker Christopher
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 1.19 per share. |
18 Jan 2024 |
5,468 |
10,056
(0%)
|
0%
|
1.2 |
6,510
|
Common Stock |
Crispina Calsada
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 1.19 per share. |
18 Jan 2024 |
5,468 |
5,782
(0%)
|
0%
|
1.2 |
6,510
|
Common Stock |
Hagan Joseph P.
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 1.19 per share. |
18 Jan 2024 |
14,580 |
57,112
(0%)
|
0%
|
1.2 |
17,359
|
Common Stock |
Aker Christopher
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Jan 2024 |
11,250 |
15,524
(0%)
|
0%
|
|
0
|
Common Stock |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Jan 2024 |
11,250 |
11,250
(0%)
|
0%
|
|
0
|
Common Stock |
Klassen Preston
|
Director, President & Head of R & D |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Jan 2024 |
120,000 |
120,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Aker Christopher
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Jan 2024 |
70,000 |
70,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph Hagan P.
|
Director, Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Jan 2024 |
30,000 |
71,692
(0%)
|
0%
|
|
0
|
Common Stock |
Joseph Hagan P.
|
Director, Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Jan 2024 |
249,000 |
249,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Jan 2024 |
85,000 |
85,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Aug 2023 |
15,000 |
15,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Aug 2023 |
15,000 |
15,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Aug 2023 |
15,000 |
15,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Aug 2023 |
1,312,500 |
1,312,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Jake R. Nunn
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Aug 2023 |
15,000 |
15,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Preston Klassen
|
Director, President & Head of R & D |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Aug 2023 |
225,000 |
225,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Christopher Aker
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Aug 2023 |
393,750 |
393,750
|
-
|
|
-
|
Stock Option (Right to Buy) |
Pascale Witz
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Aug 2023 |
15,000 |
15,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Hugh Rosen
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Aug 2023 |
15,000 |
15,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Aug 2023 |
15,000 |
15,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Aug 2023 |
375,000 |
375,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Alice Shih-hou Huang
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Aug 2023 |
15,000 |
15,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
13 Jun 2023 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
13 Jun 2023 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
13 Jun 2023 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Jake R. Nunn
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
13 Jun 2023 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Pascale Witz
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
13 Jun 2023 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Hugh Rosen
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
13 Jun 2023 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
13 Jun 2023 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Alice Shih-hou Huang
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
13 Jun 2023 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Preston Klassen
|
President & Head of R & D |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Jun 2023 |
350,000 |
350,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 0.90 per share. |
13 Apr 2023 |
222,198 |
728,388
(3%)
|
1%
|
0.9 |
200,000
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
11 Jan 2023 |
100,000 |
100,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Christopher Aker
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
11 Jan 2023 |
45,000 |
45,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
11 Jan 2023 |
45,000 |
45,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jun 2022 |
90,000 |
90,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jun 2022 |
90,000 |
90,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Jake R. Nunn
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jun 2022 |
90,000 |
90,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Pascale Witz
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jun 2022 |
90,000 |
90,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jun 2022 |
90,000 |
90,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Alice Shih-hou Huang
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Jun 2022 |
90,000 |
90,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 May 2022 |
300,000 |
300,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Christopher Aker
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 May 2022 |
70,000 |
70,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 May 2022 |
50,000 |
50,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Denis Drygin
|
Chief Scientific Officer |
Purchase of securities on an exchange or from another person at price $ 0.23 per share. |
01 Mar 2022 |
76,686 |
100,000
(0%)
|
0%
|
0.2 |
17,638
|
Common Stock |
Denis Drygin
|
Chief Scientific Officer |
Purchase of securities on an exchange or from another person at price $ 0.23 per share. |
04 Feb 2022 |
23,314 |
23,314
(0%)
|
0%
|
0.2 |
5,362
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Purchase of securities on an exchange or from another person at price $ 0.22 per share. |
12 Jan 2022 |
100,000 |
417,006
(1%)
|
0%
|
0.2 |
21,520
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Jan 2022 |
1,600,000 |
1,600,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Christopher Aker
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Jan 2022 |
480,000 |
480,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Jan 2022 |
480,000 |
480,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Denis Drygin
|
Chief Scientific Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Jan 2022 |
400,000 |
400,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 0.36 per share. |
30 Nov 2021 |
2,222,222 |
5,061,929
(24%)
|
10%
|
0.4 |
800,000
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.89 per share. |
17 May 2021 |
4,186 |
316,292
(1%)
|
0%
|
0.9 |
3,726
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 0.89 per share. |
17 May 2021 |
860 |
41,754
(0%)
|
0%
|
0.9 |
765
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
|
14 Apr 2021 |
7,585 |
0
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
Joseph P. Hagan
|
Director, President and CEO |
|
14 Apr 2021 |
75,850 |
320,478
(1%)
|
0%
|
|
-
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 1.72 per share. |
16 Feb 2021 |
4,144 |
244,628
(1%)
|
0%
|
1.7 |
7,128
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 1.72 per share. |
16 Feb 2021 |
828 |
42,614
(0%)
|
0%
|
1.7 |
1,424
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
04 Feb 2021 |
600,000 |
600,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Christopher Aker
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
04 Feb 2021 |
180,000 |
180,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
04 Feb 2021 |
150,000 |
150,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Denis Drygin
|
Chief Scientific Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
04 Feb 2021 |
120,000 |
120,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Alice Shih-hou Huang
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jan 2021 |
80,000 |
80,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.60 per share. |
14 Aug 2020 |
4,245 |
222,088
(1%)
|
0%
|
0.6 |
2,568
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 0.61 per share. |
14 Aug 2020 |
872 |
26,638
(0%)
|
0%
|
0.6 |
528
|
Common Stock |
Denis Drygin
|
Chief Scientific Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
03 Aug 2020 |
300,000 |
300,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 Jun 2020 |
23,250 |
23,250
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 Jun 2020 |
23,250 |
23,250
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.63 per share. |
15 May 2020 |
4,426 |
226,333
(1%)
|
0%
|
0.6 |
2,774
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 0.63 per share. |
15 May 2020 |
909 |
27,510
(0%)
|
0%
|
0.6 |
570
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.83 per share. |
18 Feb 2020 |
4,324 |
230,759
(1%)
|
0%
|
0.8 |
3,591
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 0.83 per share. |
18 Feb 2020 |
888 |
28,419
(0%)
|
0%
|
0.8 |
737
|
Common Stock |
Stelios Papadopoulos
|
None |
|
03 Feb 2020 |
846,320 |
2,039,521
(9%)
|
4%
|
|
-
|
Common Stock |
Stelios Papadopoulos
|
None |
|
03 Feb 2020 |
84,632 |
0
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
William H. Rastetter
|
None |
|
03 Feb 2020 |
225,940 |
390,584
(1%)
|
1%
|
|
-
|
Common Stock |
William H. Rastetter
|
None |
|
03 Feb 2020 |
22,594 |
0
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
22 Jan 2020 |
900,000 |
900,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Christopher Aker
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
22 Jan 2020 |
210,000 |
210,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
22 Jan 2020 |
150,000 |
150,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.97 per share. |
02 Jan 2020 |
8,345 |
235,083
(1%)
|
0%
|
1.0 |
8,067
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 0.97 per share. |
02 Jan 2020 |
2,239 |
29,307
(0%)
|
0%
|
1.0 |
2,164
|
Common Stock |
Anthony A. Florence
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
900,900 |
900,900
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
Anthony A. Florence
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
9,009,000 |
9,009,000
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Peter J. Barris
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
900,900 |
900,900
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
Peter J. Barris
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
9,009,000 |
9,009,000
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 Dec 2019 |
846,320 |
846,320
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 Dec 2019 |
84,632 |
84,632
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
William H. Rastetter
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 Dec 2019 |
22,594 |
22,594
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
William H. Rastetter
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 Dec 2019 |
225,940 |
225,940
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
David M. Mott
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
900,900 |
900,900
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
David M. Mott
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
9,009,000 |
9,009,000
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 Dec 2019 |
7,585 |
7,585
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 Dec 2019 |
75,850 |
75,850
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Sandell D Scott
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
9,009,000 |
9,009,000
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Sandell D Scott
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
900,900 |
900,900
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
Forest Baskett
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
900,900 |
900,900
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
Forest Baskett
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
9,009,000 |
9,009,000
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Joshua Makower
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
9,009,000 |
9,009,000
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Joshua Makower
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
900,900 |
900,900
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
Pascale Witz
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 Dec 2019 |
6,770 |
6,770
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
Pascale Witz
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 Dec 2019 |
67,700 |
67,700
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Ali Behbahani
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
9,009,000 |
9,009,000
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Ali Behbahani
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
900,900 |
900,900
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
Peter Sonsini
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
9,009,000 |
9,009,000
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Peter Sonsini
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
900,900 |
900,900
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
Carmen Chang
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
900,900 |
900,900
|
-
|
|
-
|
Class A-2 Convertible Preferred Stock |
Carmen Chang
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
24 Dec 2019 |
9,009,000 |
9,009,000
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.64 per share. |
14 Nov 2019 |
5,838 |
243,428
(1%)
|
0%
|
0.6 |
3,736
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 0.64 per share. |
14 Nov 2019 |
833 |
31,546
(0%)
|
0%
|
0.6 |
533
|
Common Stock |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Oct 2019 |
46,500 |
46,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Oct 2019 |
46,500 |
46,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Oct 2019 |
46,500 |
46,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Oct 2019 |
1,000,000 |
1,000,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Jake R. Nunn
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Oct 2019 |
46,500 |
46,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Christopher Aker
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Oct 2019 |
335,000 |
335,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Pascale Witz
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Oct 2019 |
46,500 |
46,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Hugh Rosen
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Oct 2019 |
46,500 |
46,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Oct 2019 |
46,500 |
46,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Simos Simeonidis
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Oct 2019 |
46,500 |
46,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Oct 2019 |
210,000 |
210,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.68 per share. |
01 Oct 2019 |
8,743 |
249,266
(1%)
|
0%
|
0.7 |
5,969
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 0.68 per share. |
01 Oct 2019 |
2,346 |
32,379
(0%)
|
0%
|
0.7 |
1,602
|
Common Stock |
Crispina Calsada
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Aug 2019 |
100,000 |
100,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.55 per share. |
15 Aug 2019 |
4,375 |
258,009
(1%)
|
0%
|
0.6 |
2,409
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 0.55 per share. |
15 Aug 2019 |
899 |
34,725
(0%)
|
0%
|
0.6 |
495
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 1.31 per share. |
01 Jul 2019 |
5,783 |
262,384
(1%)
|
0%
|
1.3 |
7,584
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 1.31 per share. |
01 Jul 2019 |
2,225 |
35,624
(0%)
|
0%
|
1.3 |
2,918
|
Common Stock |
Daniel R. Chevallard
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 1.31 per share. |
01 Jul 2019 |
2,669 |
77,870
(0%)
|
0%
|
1.3 |
3,500
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
14 May 2019 |
10,000 |
10,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
14 May 2019 |
188,385 |
307,519
(1%)
|
0%
|
|
0
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 1.22 per share. |
14 May 2019 |
39,352 |
268,167
(1%)
|
0%
|
1.2 |
47,966
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
14 May 2019 |
7,500 |
7,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Christopher Aker
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
14 May 2019 |
38,512 |
66,259
(0%)
|
0%
|
|
0
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 1.41 per share. |
14 May 2019 |
6,950 |
59,309
(0%)
|
0%
|
1.4 |
9,796
|
Common Stock |
Daniel R. Chevallard
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
14 May 2019 |
8,000 |
8,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Anthony A. Florence
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
3,703,704 |
3,703,704
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Anthony A. Florence
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
256,700 |
256,700
|
-
|
|
-
|
Class A-1 Convertible Preferred Stock |
Anthony A. Florence
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 1.08 per share. |
07 May 2019 |
1,136,704 |
2,052,454
(9%)
|
5%
|
1.1 |
1,227,640
|
Common Stock |
Peter J. Barris
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
256,700 |
256,700
|
-
|
|
-
|
Class A-1 Convertible Preferred Stock |
Peter J. Barris
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 1.08 per share. |
07 May 2019 |
1,136,704 |
2,052,454
(9%)
|
5%
|
1.1 |
1,227,640
|
Common Stock |
Peter J. Barris
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
3,703,704 |
3,703,704
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 May 2019 |
370,370 |
370,370
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Stelios Papadopoulos
|
Director |
Grant, award, or other acquisition of securities at price $ 1.08 per share. |
07 May 2019 |
370,370 |
1,189,872
(5%)
|
1%
|
1.1 |
400,000
|
Common Stock |
William H. Rastetter
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 May 2019 |
92,889 |
92,889
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
William H. Rastetter
|
Director |
Grant, award, or other acquisition of securities at price $ 1.08 per share. |
07 May 2019 |
92,889 |
154,223
(0%)
|
0%
|
1.1 |
100,320
|
Common Stock |
David M. Mott
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
3,703,704 |
3,703,704
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
David M. Mott
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
256,700 |
256,700
|
-
|
|
-
|
Class A-1 Convertible Preferred Stock |
David M. Mott
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 1.08 per share. |
07 May 2019 |
1,136,704 |
2,052,454
(9%)
|
5%
|
1.1 |
1,227,640
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 1.08 per share. |
07 May 2019 |
33,194 |
64,542
(0%)
|
0%
|
1.1 |
35,850
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 May 2019 |
33,194 |
33,194
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Sandell D Scott
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
3,703,704 |
3,703,704
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Sandell D Scott
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
256,700 |
256,700
|
-
|
|
-
|
Class A-1 Convertible Preferred Stock |
Sandell D Scott
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 1.08 per share. |
07 May 2019 |
1,136,704 |
2,052,454
(9%)
|
5%
|
1.1 |
1,227,640
|
Common Stock |
Forest Baskett
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
3,703,704 |
3,703,704
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Forest Baskett
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 1.08 per share. |
07 May 2019 |
1,136,704 |
2,052,454
(9%)
|
5%
|
1.1 |
1,227,640
|
Common Stock |
Forest Baskett
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
256,700 |
256,700
|
-
|
|
-
|
Class A-1 Convertible Preferred Stock |
Joshua Makower
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 1.08 per share. |
07 May 2019 |
1,136,704 |
2,052,454
(9%)
|
5%
|
1.1 |
1,227,640
|
Common Stock |
Joshua Makower
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
256,700 |
256,700
|
-
|
|
-
|
Class A-1 Convertible Preferred Stock |
Joshua Makower
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
3,703,704 |
3,703,704
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Pascale Witz
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
07 May 2019 |
29,630 |
29,630
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Pascale Witz
|
Director |
Grant, award, or other acquisition of securities at price $ 1.08 per share. |
07 May 2019 |
29,630 |
37,849
(0%)
|
0%
|
1.1 |
32,000
|
Common Stock |
Ali Behbahani
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
3,703,704 |
3,703,704
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Ali Behbahani
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
256,700 |
256,700
|
-
|
|
-
|
Class A-1 Convertible Preferred Stock |
Ali Behbahani
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 1.08 per share. |
07 May 2019 |
1,136,704 |
2,052,454
(9%)
|
5%
|
1.1 |
1,227,640
|
Common Stock |
Peter Sonsini
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 1.08 per share. |
07 May 2019 |
1,136,704 |
2,052,454
(9%)
|
5%
|
1.1 |
1,227,640
|
Common Stock |
Peter Sonsini
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
3,703,704 |
3,703,704
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Peter Sonsini
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
256,700 |
256,700
|
-
|
|
-
|
Class A-1 Convertible Preferred Stock |
Carmen Chang
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
3,703,704 |
3,703,704
|
-
|
|
-
|
Common Stock Purchase Warrant (Right to Buy) |
Carmen Chang
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
07 May 2019 |
256,700 |
256,700
|
-
|
|
-
|
Class A-1 Convertible Preferred Stock |
Carmen Chang
|
Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 1.08 per share. |
07 May 2019 |
1,136,704 |
2,052,454
(9%)
|
5%
|
1.1 |
1,227,640
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.98 per share. |
01 Apr 2019 |
5,842 |
31,348
(0%)
|
0%
|
1.0 |
5,731
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Sale of securities on an exchange or to another person at price $ 0.98 per share. |
01 Apr 2019 |
2,710 |
6,287
(0%)
|
0%
|
1.0 |
2,659
|
Common Stock |
Daniel R. Chevallard
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 0.98 per share. |
01 Apr 2019 |
3,253 |
9,372
(0%)
|
0%
|
1.0 |
3,192
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.95 per share. |
05 Feb 2019 |
65,000 |
84,148
(0%)
|
0%
|
1.0 |
61,750
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
05 Feb 2019 |
65,000 |
65,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Christopher Aker
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
05 Feb 2019 |
25,000 |
27,747
(0%)
|
0%
|
|
0
|
Common Stock |
Christopher Aker
|
Sr. VP & General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
05 Feb 2019 |
25,000 |
25,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Daniel R. Chevallard
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
05 Feb 2019 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Daniel R. Chevallard
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.95 per share. |
05 Feb 2019 |
30,000 |
34,578
(0%)
|
0%
|
1.0 |
28,500
|
Common Stock |
Timothy Michael Wright
|
Chief R & D Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
05 Feb 2019 |
40,000 |
40,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Timothy Michael Wright
|
Chief R & D Officer |
Grant, award, or other acquisition of securities at price $ 0.95 per share. |
05 Feb 2019 |
40,000 |
62,893
(0%)
|
0%
|
1.0 |
38,000
|
Common Stock |
Stelios Papadopoulos
|
None |
Purchase of securities on an exchange or from another person at price $ 1.09 per share. |
28 Dec 2018 |
50,000 |
835,073
(9%)
|
0%
|
1.1 |
54,570
|
Common Stock |
Stelios Papadopoulos
|
None |
Purchase of securities on an exchange or from another person at price $ 0.95 per share. |
26 Dec 2018 |
90,000 |
758,672
(8%)
|
1%
|
1.0 |
85,878
|
Common Stock |
Stelios Papadopoulos
|
None |
Purchase of securities on an exchange or from another person at price $ 1.04 per share. |
26 Dec 2018 |
26,401 |
785,073
(8%)
|
0%
|
1.0 |
27,460
|
Common Stock |
Kathryn J. Collier
|
None |
Purchase of securities on an exchange or from another person at price $ 1.41 per share. |
16 Nov 2018 |
7,100 |
27,596
(0%)
|
0%
|
1.4 |
10,011
|
Common Stock |
Stelios Papadopoulos
|
None |
Purchase of securities on an exchange or from another person at price $ 1.33 per share. |
15 Nov 2018 |
200,000 |
368,672
(4%)
|
2%
|
1.3 |
265,080
|
Common Stock |
Stelios Papadopoulos
|
None |
Purchase of securities on an exchange or from another person at price $ 1.38 per share. |
15 Nov 2018 |
300,000 |
668,672
(7%)
|
3%
|
1.4 |
415,470
|
Common Stock |
Stelios Papadopoulos
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
1,458 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Nov 2018 |
20,910 |
168,672
(1%)
|
0%
|
|
0
|
Common Stock |
Stelios Papadopoulos
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
4,583 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
6,250 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
2,500 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
3,051 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
1,458 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
1,458 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
152 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
2,500 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
4,583 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
6,250 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
2,500 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
3,051 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
1,458 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Nov 2018 |
23,258 |
79,672
(0%)
|
0%
|
|
0
|
Common Stock |
William H. Rastetter
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
1,458 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
1,458 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
1,458 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
10,625 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
1,875 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
625 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
625 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
1,458 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
625 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
1,458 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
416 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
1,458 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
1,458 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
416 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
1,458 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
3,051 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
2,500 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
6,250 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
4,583 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Nov 2018 |
40,339 |
44,131
(0%)
|
0%
|
|
0
|
Common Stock |
Pascale Witz
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Nov 2018 |
15,833 |
19,625
(0%)
|
0%
|
|
0
|
Common Stock |
Pascale Witz
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
5,000 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Pascale Witz
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
4,583 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Pascale Witz
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
6,250 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Hugh Rosen
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
6,250 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Hugh Rosen
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
4,583 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Hugh Rosen
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Nov 2018 |
19,245 |
22,756
(0%)
|
0%
|
|
0
|
Common Stock |
Hugh Rosen
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
5,912 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Hugh Rosen
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
2,500 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
12 Nov 2018 |
16,874 |
20,496
(0%)
|
0%
|
|
0
|
Common Stock |
Kathryn J. Collier
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
9,166 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
3,125 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
None |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
12 Nov 2018 |
4,583 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Jun 2018 |
55,000 |
55,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Jun 2018 |
55,000 |
55,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Jun 2018 |
55,000 |
55,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Pascale Witz
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Jun 2018 |
55,000 |
55,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Hugh Rosen
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Jun 2018 |
55,000 |
55,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
None |
Grant, award, or other acquisition of securities at price $ 0.74 per share. |
01 Jun 2018 |
7,695 |
7,695
(0%)
|
0%
|
0.7 |
5,694
|
Common Stock |
Kathryn J. Collier
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Jun 2018 |
55,000 |
55,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 May 2018 |
75,000 |
75,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 May 2018 |
75,000 |
75,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 May 2018 |
75,000 |
75,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 May 2018 |
725,000 |
725,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Pascale Witz
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 May 2018 |
75,000 |
75,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Daniel R. Chevallard
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 May 2018 |
250,000 |
250,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Hugh Rosen
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 May 2018 |
75,000 |
75,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Timothy Michael Wright
|
Chief R & D Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 May 2018 |
350,000 |
350,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Mark Albert Deeg
|
Chief Medical Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 May 2018 |
100,000 |
100,000
|
-
|
|
-
|
Common Stock (Right to Buy) |
Kathryn J. Collier
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
17 May 2018 |
37,500 |
37,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kathryn J. Collier
|
None |
Grant, award, or other acquisition of securities at price $ 0.64 per share. |
14 Apr 2018 |
60,234 |
60,234
(0%)
|
0%
|
0.6 |
38,550
|
Common Stock |
Kathryn J. Collier
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
14 Apr 2018 |
110,000 |
110,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
05 Jan 2018 |
1,000,000 |
1,000,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Daniel R. Chevallard
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
05 Jan 2018 |
350,000 |
350,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Timothy Michael Wright
|
Chief R & D Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
05 Jan 2018 |
500,000 |
500,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Mark Albert Deeg
|
Chief Medical Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
05 Jan 2018 |
175,000 |
175,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Grant, award, or other acquisition of securities at price $ 0.89 per share. |
04 Dec 2017 |
96,629 |
1,797,306
(1%)
|
0%
|
0.9 |
86,000
|
Common Stock |
William H. Rastetter
|
None |
Grant, award, or other acquisition of securities at price $ 0.89 per share. |
04 Dec 2017 |
69,662 |
694,387
(0%)
|
0%
|
0.9 |
61,999
|
Common Stock |
David Baltimore
|
None |
Grant, award, or other acquisition of securities at price $ 0.89 per share. |
04 Dec 2017 |
60,674 |
60,674
(0%)
|
0%
|
0.9 |
54,000
|
Common Stock |
Mark G. Foletta
|
None |
Grant, award, or other acquisition of securities at price $ 0.89 per share. |
04 Dec 2017 |
71,910 |
81,910
(0%)
|
0%
|
0.9 |
64,000
|
Common Stock |
Pascale Witz
|
None |
Grant, award, or other acquisition of securities at price $ 0.89 per share. |
04 Dec 2017 |
60,674 |
60,674
(0%)
|
0%
|
0.9 |
54,000
|
Common Stock |
Hugh Rosen
|
None |
Grant, award, or other acquisition of securities at price $ 0.89 per share. |
04 Dec 2017 |
56,179 |
56,179
(0%)
|
0%
|
0.9 |
49,999
|
Common Stock |
Timothy Michael Wright
|
Chief R & D Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
04 Dec 2017 |
100,000 |
100,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Purchase of securities on an exchange or from another person at price $ 0.91 per share. |
25 Jul 2017 |
1,000,000 |
1,770,677
(1%)
|
0%
|
0.9 |
910,000
|
Common Stock |
William H. Rastetter
|
None |
Purchase of securities on an exchange or from another person at price $ 0.91 per share. |
25 Jul 2017 |
274,725 |
624,625
(0%)
|
0%
|
0.9 |
250,000
|
Common Stock |
Joseph P. Hagan
|
Director, President and CEO |
Purchase of securities on an exchange or from another person at price $ 0.91 per share. |
25 Jul 2017 |
219,780 |
241,297
(0%)
|
0%
|
0.9 |
200,000
|
Common Stock |
Daniel R. Chevallard
|
Chief Financial Officer |
Purchase of securities on an exchange or from another person at price $ 0.91 per share. |
25 Jul 2017 |
54,945 |
59,415
(0%)
|
0%
|
0.9 |
50,000
|
Common Stock |
Timothy Michael Wright
|
Chief R & D Officer |
Purchase of securities on an exchange or from another person at price $ 0.91 per share. |
25 Jul 2017 |
274,725 |
274,725
(0%)
|
0%
|
0.9 |
250,000
|
Common Stock |
Mark Albert Deeg
|
Chief Medical Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
22 Jun 2017 |
100,000 |
100,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Jun 2017 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Jun 2017 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Jun 2017 |
30,000 |
30,000
|
-
|
|
-
|
Common Stock (Option to Buy) |
Mark G. Foletta
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Jun 2017 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Pascale Witz
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Jun 2017 |
60,000 |
60,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Hugh Rosen
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Jun 2017 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Daniel R. Chevallard
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 May 2017 |
100,000 |
100,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
04 May 2017 |
750,000 |
750,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Timothy Michael Wright
|
Chief R & D Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
04 May 2017 |
350,000 |
350,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Purchase of securities on an exchange or from another person at price $ 1.23 per share. |
21 Mar 2017 |
300,000 |
700,677
(1%)
|
0%
|
1.2 |
368,100
|
Common Stock |
Stelios Papadopoulos
|
None |
Purchase of securities on an exchange or from another person at price $ 1.20 per share. |
21 Mar 2017 |
200,000 |
400,677
(0%)
|
0%
|
1.2 |
239,800
|
Common Stock |
William H. Rastetter
|
None |
Purchase of securities on an exchange or from another person at price $ 1.15 per share. |
07 Mar 2017 |
250,000 |
350,000
(0%)
|
0%
|
1.2 |
287,500
|
Common Stock |
Paul C. Grint
|
Director, President & CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Feb 2017 |
410,000 |
410,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Chief Operating Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Feb 2017 |
160,000 |
160,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Timothy Michael Wright
|
Chief R & D Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
15 Feb 2017 |
32,412 |
32,412
|
-
|
|
-
|
Stock Option (Right to Buy) |
Paul C. Grint
|
Director, President & CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Jan 2017 |
130,000 |
130,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Chief Operating Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Jan 2017 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Paul C. Grint
|
Director, President & CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
05 Oct 2016 |
186,640 |
186,640
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Chief Operating Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
05 Oct 2016 |
59,625 |
59,625
|
-
|
|
-
|
Stock Option (Right to Buy) |
Timothy Michael Wright
|
Chief R & D Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
03 Oct 2016 |
450,000 |
450,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
02 Jun 2016 |
36,620 |
36,620
|
-
|
|
-
|
Stock Option (Right to Buy) |
Mark G. Foletta
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
02 Jun 2016 |
36,620 |
36,620
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
02 Jun 2016 |
36,620 |
36,620
|
-
|
|
-
|
Stock Option (Right to Buy) |
Douglas E. Williams
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
02 Jun 2016 |
36,620 |
36,620
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
02 Jun 2016 |
36,620 |
36,620
|
-
|
|
-
|
Stock Option (Right to Buy) |
Hugh Rosen
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
02 Jun 2016 |
70,952 |
70,952
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Chief Operating Officer |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
03 Mar 2016 |
10,000 |
10,000
|
-
|
|
-
|
Common Stock |
Paul C. Grint
|
Director, President & CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
04 Feb 2016 |
265,000 |
265,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Joseph P. Hagan
|
Chief Operating Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
04 Jan 2016 |
420,000 |
420,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Paul C. Grint
|
Director, President & CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Dec 2015 |
30,000 |
30,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Mark G. Foletta
|
None |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
13 Aug 2015 |
10,000 |
10,000
|
-
|
|
-
|
Common Stock |
Stelios Papadopoulos
|
None |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Aug 2015 |
17,500 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Aug 2015 |
17,500 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Aug 2015 |
15,677 |
1,823
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Aug 2015 |
17,500 |
167,500
|
-
|
|
-
|
Common Stock |
Stelios Papadopoulos
|
None |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Aug 2015 |
17,500 |
185,000
|
-
|
|
-
|
Common Stock |
Stelios Papadopoulos
|
None |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
07 Aug 2015 |
15,677 |
200,677
|
-
|
|
-
|
Common Stock |
William H. Rastetter
|
None |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
20 Jul 2015 |
38,765 |
38,765
|
-
|
|
-
|
Common Stock |
William H. Rastetter
|
None |
Purchase of securities on an exchange or from another person at price $ 0.00 per share. |
20 Jul 2015 |
61,235 |
100,000
|
-
|
|
-
|
Common Stock |
Paul C. Grint
|
Director, President & CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 Jun 2015 |
500,000 |
500,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Baltimore
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Jun 2015 |
17,500 |
17,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Mark G. Foletta
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Jun 2015 |
17,500 |
17,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
William H. Rastetter
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Jun 2015 |
17,500 |
17,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Bruce L.A. Carter
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Jun 2015 |
17,500 |
17,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Bruce L.A. Carter
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Jun 2015 |
17,500 |
17,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Douglas E. Williams
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Jun 2015 |
17,500 |
17,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Stelios Papadopoulos
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
10 Jun 2015 |
17,500 |
17,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Apr 2015 |
73,929 |
134,358
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Apr 2015 |
66,071 |
68,287
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Apr 2015 |
60,000 |
8,287
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Apr 2015 |
73,929 |
77,634
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
17 Apr 2015 |
73,929 |
3,705
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Apr 2015 |
66,071 |
69,776
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
17 Apr 2015 |
66,071 |
3,705
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Apr 2015 |
60,000 |
63,705
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
17 Apr 2015 |
60,000 |
3,705
|
-
|
|
-
|
Common Stock |
Bruce L.A. Carter
|
None |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
13 Apr 2015 |
20,000 |
10,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Bruce L.A. Carter
|
None |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
13 Apr 2015 |
20,000 |
20,000
|
-
|
|
-
|
Common Stock |
Bruce L.A. Carter
|
None |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
13 Apr 2015 |
20,000 |
0
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
05 Mar 2015 |
89,230 |
208,287
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
05 Mar 2015 |
89,230 |
91,696
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
05 Mar 2015 |
65,614 |
26,082
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
05 Mar 2015 |
23,616 |
2,466
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
27 Feb 2015 |
70 |
297,517
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
27 Feb 2015 |
70 |
2,536
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
27 Feb 2015 |
70 |
2,466
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
30 Jan 2015 |
3,300 |
299,987
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
30 Jan 2015 |
2,400 |
297,587
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
30 Jan 2015 |
3,300 |
5,766
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
30 Jan 2015 |
3,300 |
2,466
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
30 Jan 2015 |
2,400 |
4,866
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
30 Jan 2015 |
2,400 |
2,466
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
28 Jan 2015 |
71,345 |
8,655
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
28 Jan 2015 |
8,655 |
0
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
28 Jan 2015 |
85,000 |
363,287
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
28 Jan 2015 |
60,000 |
303,287
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
28 Jan 2015 |
85,000 |
87,466
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
28 Jan 2015 |
72,011 |
15,455
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
28 Jan 2015 |
12,989 |
2,466
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
28 Jan 2015 |
60,000 |
62,466
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
28 Jan 2015 |
33,773 |
28,693
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
28 Jan 2015 |
26,227 |
2,466
|
-
|
|
-
|
Common Stock |
Stelios Papadopoulos
|
None |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
12 Dec 2014 |
150,000 |
150,000
|
-
|
|
-
|
Common Stock |
Stelios Papadopoulos
|
None |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
12 Dec 2014 |
150,000 |
0
|
-
|
|
-
|
Stock Option (Right to Buy) |
Paul Grint
|
Chief Medical Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
02 Dec 2014 |
50,870 |
50,870
|
-
|
|
-
|
Stock Option (Right to Buy) |
Neil Gibson
|
Chief Scientific Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
02 Dec 2014 |
90,378 |
90,378
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
02 Dec 2014 |
231,634 |
231,634
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Szekeres
|
Chief Business Officer & GC |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
02 Dec 2014 |
81,101 |
81,101
|
-
|
|
-
|
Stock Option (Right to Buy) |
Neil Gibson
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
28 Nov 2014 |
2,500 |
82,500
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
28 Nov 2014 |
1,000 |
81,500
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
28 Nov 2014 |
2,500 |
111,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Neil Gibson
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
28 Nov 2014 |
1,500 |
80,000
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
03 Nov 2014 |
1,279,411 |
5,516,305
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
29 Oct 2014 |
2,500 |
114,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Neil Gibson
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
29 Oct 2014 |
1,100 |
81,400
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
29 Oct 2014 |
2,500 |
82,500
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
29 Oct 2014 |
1,200 |
80,200
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
29 Oct 2014 |
200 |
80,000
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
29 Oct 2014 |
1,400 |
4,571
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
29 Oct 2014 |
2,005 |
2,566
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
29 Oct 2014 |
3,505 |
5,971
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
29 Oct 2014 |
100 |
2,466
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
29 Oct 2014 |
3,505 |
448,287
|
-
|
|
-
|
Stock Option (Right to Buy) |
Neil Gibson
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
22 Oct 2014 |
3,300 |
83,300
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
22 Oct 2014 |
3,300 |
116,500
|
-
|
|
-
|
Stock Option (Right to Buy) |
Neil Gibson
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
22 Oct 2014 |
3,300 |
80,000
|
-
|
|
-
|
Common Stock |
Paul Grint
|
Chief Medical Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Oct 2014 |
40,000 |
40,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Neil Gibson
|
Chief Scientific Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Oct 2014 |
40,000 |
40,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Oct 2014 |
88,000 |
88,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
David Szekeres
|
CBO and General Counsel |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
20 Oct 2014 |
40,000 |
40,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Oct 2014 |
300 |
451,792
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
17 Oct 2014 |
400 |
2,466
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Oct 2014 |
300 |
2,766
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
17 Oct 2014 |
300 |
2,466
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Oct 2014 |
400 |
2,866
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 Oct 2014 |
400 |
452,092
|
-
|
|
-
|
Stock Option (Right to Buy) |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
15 Oct 2014 |
3,000 |
6,908,800
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
15 Oct 2014 |
4,800 |
6,911,800
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
15 Oct 2014 |
4,300 |
6,916,600
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
09 Oct 2014 |
400 |
2,466
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
09 Oct 2014 |
105 |
452,892
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
09 Oct 2014 |
400 |
452,492
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
09 Oct 2014 |
400 |
2,866
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
09 Oct 2014 |
105 |
2,466
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
09 Oct 2014 |
105 |
2,571
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
08 Oct 2014 |
3,300 |
6,927,650
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
08 Oct 2014 |
2,000 |
6,920,900
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
08 Oct 2014 |
4,750 |
6,922,900
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
01 Oct 2014 |
3,750 |
6,934,250
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
01 Oct 2014 |
3,300 |
6,930,950
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
01 Oct 2014 |
3,250 |
6,938,000
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
30 Sep 2014 |
2,300 |
452,997
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
30 Sep 2014 |
2,300 |
2,466
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President and CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
30 Sep 2014 |
2,300 |
4,766
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
24 Sep 2014 |
3,750 |
6,946,250
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
24 Sep 2014 |
2,500 |
6,943,750
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
24 Sep 2014 |
2,500 |
6,941,250
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
17 Sep 2014 |
2,100 |
6,955,600
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
17 Sep 2014 |
4,100 |
6,950,000
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
17 Sep 2014 |
1,500 |
6,954,100
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
11 Sep 2014 |
2,000 |
122,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Neil Gibson
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
11 Sep 2014 |
2,000 |
82,000
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
11 Sep 2014 |
2,000 |
80,000
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
11 Sep 2014 |
2,200 |
80,000
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
11 Sep 2014 |
2,200 |
82,200
|
-
|
|
-
|
Common Stock |
Neil Gibson
|
Chief Scientific Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
11 Sep 2014 |
2,200 |
119,800
|
-
|
|
-
|
Stock Option (Right to Buy) |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
10 Sep 2014 |
2,000 |
6,964,600
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
10 Sep 2014 |
3,500 |
6,957,700
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
10 Sep 2014 |
3,400 |
6,961,200
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
03 Sep 2014 |
1,650 |
6,975,000
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
03 Sep 2014 |
6,000 |
6,969,000
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
03 Sep 2014 |
2,400 |
6,966,600
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President & CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
28 Aug 2014 |
3,505 |
455,297
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President & CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
28 Aug 2014 |
3,505 |
3,505
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President & CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
28 Aug 2014 |
3,505 |
0
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
27 Aug 2014 |
1,500 |
6,976,650
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
27 Aug 2014 |
2,000 |
6,978,150
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
27 Aug 2014 |
1,500 |
6,980,150
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
20 Aug 2014 |
2,500 |
6,986,900
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
20 Aug 2014 |
5,250 |
6,981,650
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
20 Aug 2014 |
3,000 |
6,989,400
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
13 Aug 2014 |
2,250 |
6,995,600
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
13 Aug 2014 |
1,450 |
6,992,400
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
13 Aug 2014 |
1,750 |
6,993,850
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
06 Aug 2014 |
3,150 |
7,002,300
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
06 Aug 2014 |
2,600 |
6,999,700
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
06 Aug 2014 |
1,850 |
6,997,850
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President & CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
05 Aug 2014 |
3,505 |
458,802
|
-
|
|
-
|
Stock Option (Right to Buy) |
Kleanthis G. Xanthopoulos
|
Director, President & CEO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
05 Aug 2014 |
3,505 |
3,505
|
-
|
|
-
|
Common Stock |
Kleanthis G. Xanthopoulos
|
Director, President & CEO |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
05 Aug 2014 |
3,505 |
0
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
30 Jul 2014 |
1,000 |
7,009,800
|
-
|
|
-
|
Common Stock |
B. Lynne Parshall
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 0.00 per share. |
30 Jul 2014 |
2,600 |
7,005,450
|
-
|
|
-
|
Common Stock |